According to Crunchbase, the U.S. startup sector has seen a significant increase in large funding deals, with biotech and healthcare startups leading the way, securing numerous funding rounds exceeding $100 million. This trend is driven by advancements in technology, such as AI in drug discovery, as well as a greater focus on healthcare innovation following the pandemic, supportive regulatory conditions, and an aging global population.
Technological advancements, notably the integration of AI in drug discovery and more, are accelerating the process and attracting substantial investment despite challenges posed by data complexity.
To learn more about this topic, read the recent Labiotech article by Jules Adams, featuring commentary from LongeVC managing partner Sergey Jakimov.
Technological advancements, notably the integration of AI in drug discovery and more, are accelerating the process and attracting substantial investment despite challenges posed by data complexity.
To learn more about this topic, read the recent Labiotech article by Jules Adams, featuring commentary from LongeVC managing partner Sergey Jakimov.